Detection of MEAF6‐PHF1 translocation in an endometrial stromal nodule. Issue 12 (3rd September 2020)

• Record Type: Journal Article
• Authors: Nomura, Yusuke; Tamura, Daisuke; Horie, Masafumi; Sato, Masakazu; Sasaki, Shinya; Yamamoto, Yohei; Kudo‐Asabe, Yukitsugu; Umakoshi, Michinobu; Koyama, Kei; Makino, Kenichi; Takashima, Shinogu; Imai, Kazuhiro; Minamiya, Yoshihiro; Munakata, Satoru; Yachida, Shinichi; Terada, Yukihiro; Goto, Akiteru; Maeda, Daichi
• Is Part Of: Genes, chromosomes & cancer. Volume 59:Issue 12(2020)
• Page Start: 702
• Page End: 708
• Publication Date: 2020-09-03
• Subjects: endometrial stromal nodule -- fusion -- MEAF6 -- next generation sequencing -- PHF1; Cancer -- Genetic aspects -- Periodicals; 616.994042
• DOI: 10.1002/gcc.22892
• Languages: English
• ISSNs: 1045-2257

Abstract

Abstract: Endometrial stromal nodule (ESN) and low‐grade endometrial stromal sarcoma (LG‐ESS) are rare uterine tumors known as endometrial stromal tumors (ESTs). In addition to their similarity in morphological features, recent studies have shown that these two tumors share common genetic alterations. In particular, JAZF1‐SUZ12 fusion is found with high frequency in both ESN and LG‐ESS. In LG‐ESS, some minor fusions have also been described, which include rearrangements involving PHF1 and its partner genes, such as JAZF1, EPC1, MEAF6, BRD8, EPC2, and MBTD1 . Because of the rarity of ESN, genetic alterations other than JAZF1 fusion have not been investigated in detail. In this study, we performed a next‐generation sequencing‐based analysis in a case of ESN with peripheral metaplastic bone formation and detected MEAF6‐PHF1 fusion, which has been reported in a small subset of uterine LG‐ESSs and soft tissue ossifying fibromyxoid tumors. The finding that MEAF6‐PHF1 fusion is a background genetic abnormality detected both in ESN and LG‐ESS, along with JAZF1‐SUZ12, provides further support for the similarity and continuum between these two types of ESTs. Furthermore, the association between metaplastic bone formation and MEAF6‐PHF1 fusion may not be limited to soft tissue tumors.